Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Blake Insomnia Therapeutics, Inc. (OTC: BKIT).

Full DD Report for BKIT

You must become a subscriber to view this report.


Recent News from (OTC: BKIT)

OTC Markets Group Announces Lists of Compliance Downgrades and Caveat Emptor Designations for the Month of November
NEW YORK , Dec. 4, 2017 /PRNewswire/ --   OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lists of   downgrades from its respective OTCQX® and OTCQB® markets and Caveat Emptor Designa...
Source: PR Newswire
Date: December, 04 2017 07:00
Blake Insomnia Therapeutics Inc. Announces Submitting Clinical Trial Application for Phase II Clinical Testing
NEW YORK, Aug. 25, 2017 (GLOBE NEWSWIRE) -- Blake Insomnia Therapeutics Inc. (OTCQB:BKIT), a New York based pharmaceutical company devoted to improving quality of life for people with insomnia, is excited to announce it has submitted its clinical trial application (CTA) for Phase II clinica...
Source: GlobeNewswire
Date: August, 25 2017 09:30
NetworkNewsBreaks - Top 10 Mid-day Percentage Gainers on June 16, 2017
Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: GBLX 7.60% – News: CEO’s interview published in an article GEVO 4.84% – News: Stockholders vote to clear way for Whitebox deb...
Source: NetworkNewsWire
Date: June, 16 2017 13:00
Blake Insomnia Therapeutics Inc. Announces Appointment of Morten Albrechtsen to its Board of Directors
NEW YORK, June 16, 2017 (GLOBE NEWSWIRE) -- Blake Insomnia Therapeutics Inc. (OTCQB:BKIT), a New York based pharmaceutical company devoted to improving quality of life for people with insomnia, is pleased to announce the appointment of Morten Albrechtsen, to its Board of Directors. Morte...
Source: GlobeNewswire
Date: June, 16 2017 09:00
Blake Insomnia Therapeutics Inc. Announces Appointment of Kyle Sarwal and Ajit Johal to its Board of Directors
NEW YORK, May 25, 2017 (GLOBE NEWSWIRE) -- Blake Insomnia Therapeutics Inc. (OTCQB:BKIT) a New York based pharmaceutical company is pleased to announce the appointment of Kyle Sarwal and Ajit Johal to its Board of Directors. Mr. Sarwal is a director and business development expert for SA...
Source: GlobeNewswire
Date: May, 25 2017 06:57
Blake Insomnia Therapeutics Inc. Announces Appointment of Dr. Eric Leire to its Board of Directors
NEW YORK, May 09, 2017 (GLOBE NEWSWIRE) -- Blake Insomnia Therapeutics Inc. (OTCQB:BKIT) a New York based pharmaceutical company is pleased to announce the appointment of Dr. Eric Leire to join CEO Birger Jan Olsen on its Board of Directors. Dr. Leire has currently been the CEO of DanDri...
Source: GlobeNewswire
Date: May, 09 2017 13:20
NetworkNewsBreaks - Top 10 Mid-day Percentage Gainers on March 2, 2017
Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: ALQA 27.11% – News: Presenting at Cowen and Company 37th Annual Health Care Conference on March 8 VBIO 19.65% – News: Develops propr...
Source: NetworkNewsWire
Date: March, 02 2017 12:48
Blake Insomnia Therapeutics and Sajo Consulting Introduce Clinical Trial Team Members
NEW YORK, March 02, 2017 (GLOBE NEWSWIRE) -- Blake Insomnia Therapeutics Inc. (OTCQB:BKIT) and Sajo Consulting LLC are pleased to introduce the team appointed to conduct clinical trials of its insomnia products using Blake’s proprietary Zleepax™ formula: Christian Schutz &...
Source: GlobeNewswire
Date: March, 02 2017 09:49
Blake Insomnia Therapeutics Inc. Closes Joint Venture with Sajo Consulting LLC
NEW YORK, Feb. 25, 2017 (GLOBE NEWSWIRE) -- Blake Insomnia Therapeutics Inc. (OTCQB:BKIT) and Sajo Consulting LLC are pleased to announce completion of a joint venture agreement for the development and commercialization of a series of oral drug products to aid in the treatment of insomnia. ...
Source: GlobeNewswire
Date: February, 24 2017 20:08
Blake Insomnia Therapeutics Inc. enters a joint development with Sajo Consulting LLC
NEW YORK, Feb. 08, 2017 (GLOBE NEWSWIRE) -- Blake Insomnia Therapeutics Inc. (OTCQB:BKIT) and Sajo Consulting LLC are pleased to announce entry into a Letter of Intent to provide joint development and commercialization of Zleepax™, in combination with formulations to produce a series...
Source: GlobeNewswire
Date: February, 08 2017 16:54

 


About Blake Insomnia Therapeutics, Inc. (OTC: BKIT)

Logo for Blake Insomnia Therapeutics, Inc. (OTC: BKIT)

Blake Insomnia Therapeutics, Inc. is a New York based pharmaceutical company devoted to improving nighttime and daytime quality of life for people with insomnia. Our patent pending compound, Zleepax ZLX , has demonstrated efficacy without causing side effects which has been identified as the No. problem with current sleep medications.

 

Contact Information

 

 

Current Management

  • Birger Jan Olsen / CEO, CFO, President, Treasurer
    • Founder and CEO Birger Jan Olsen is a seasoned executive, inventor and marketer who has spent over years working primarily in pharmaceuticals and medical devices. In addition to Blake Insomnia Therapeutics, Birger has founded some business, including the pioneering neuromarketing company Mindmetic and ProjektGruppen, a successful pharmafocused marketing agency. As an inventor, Birger developed Blake s patentpending ZLX sleep medicine compound, along with a patented method for automatically interpreting brain activity, a complianceboosting dosing device for osteoporosis patients, acquired by Roche Pharmaceuticals, and the widely used Globase automated marketing tool, acquired by AdPepper. Birger s careerlong focus on startups has given him a wealth of experience with earlystage business processes, including fundraising and early organizational development.
  • Jillian Sidoti / Securities Counsel

Current Share Structure

  • Market Cap: $2,053,842 - 03/16/2018
  • Authorized: 100,000,000 - 03/01/2018
  • Issue and Outstanding: 31,597,572 - 03/01/2018
  • Float: 10,597,572 - 10/01/2016

 


Recent Filings from (OTC: BKIT)

Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: April, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 12 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: September, 06 2017
Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act
Filing Type: DFiling Source: edgar
Filing Date: September, 06 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: July, 17 2017
Filing by person(s) reporting owned shares of common stock in a public company >5%
Filing Type: SC 13DFiling Source: edgar
Filing Date: July, 13 2017
Filing by person(s) reporting owned shares of common stock in a public company >5%
Filing Type: SC 13DFiling Source: edgar
Filing Date: July, 13 2017
OTCQB Certification - OTCQB Certification
Filing Type: OTCQB Certification - OTCQB CertificationFiling Source: OTC Markets
Filing Date: April, 28 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 18 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: April, 18 2017

 

 


Daily Technical Chart for (OTC: BKIT)

Daily Technical Chart for (OTC: BKIT)


Stay tuned for daily updates and more on (OTC: BKIT)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: BKIT)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

OTC Report
@OTCReporter

 

 


Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BKIT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of BKIT and does not buy, sell, or trade any shares of BKIT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/